We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Aims to Minimize Potential for Coercion in Updated Clinical Trial Informed Consent Requirements
FDA Aims to Minimize Potential for Coercion in Updated Clinical Trial Informed Consent Requirements
Sponsors designing trials involving certain vulnerable patient populations such as limited or non-English speakers, dementia or traumatic brain injury sufferers and children will soon face greater scrutiny from institutional review boards under newly issued FDA guidance.